ReviewPharmaceutics2024
Targeting the Gut: A Systematic Review of Specific Drug Nanocarriers.
Review in Pharmaceutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 37 citations in OpenAlex.
- Hyaluronic acid-RSC pharmaceutics · 2026Article
- Review
- Liposomal drug delivery for lung cancer therapy: progress, challenges, and future perspectives.Molecular cancer · 2026Review
- Punicic acid ethyl ester, a superior absorption-enhancer over pomegranate seed oil, dramatically improves quercetin bioavailabilityInternational journal of pharmaceutics: X · 2026Article
- Detergent Conjugation Decouples Chlorpromazine Solubility from Antibacterial Activity against Bacteria Relevant for Gut Microbiota.Bioconjugate chemistry · 2026Article
- Article
- Polysaccharide-functionalized gold, silver, and iron oxide nanoparticles for siRNA delivery: The role of artificial intelligence in design and optimization.Materials today. Bio · 2026Review
- Genesis, Health Benefits, and Future Perspectives of Probiotics: Exploring Endogenous and Exogenous Classes, Innovations, and Research Gaps.Probiotics and antimicrobial proteins · 2026Review
- Advancements and Challenges in Gastroretentive Drug Delivery Systems: A Comprehensive Review of Research Innovation, Technologies, and Clinical Applications.Recent advances in drug delivery and formulation · 2026Review
- Emerging nanocarrier systems for the enhanced delivery of active pharmaceutical ingredients to the intestine.Nanomedicine (London, England) · 2025Review
- Nanoparticle-Driven Modulation of Mucosal Immunity and Interplay with the Microbiome.Journal of microbiology and biotechnology · 2025Review
- Plant cell-inspired colon-targeted cargo delivery systems with dual-triggered release mechanisms.Science advances · 2025Article
- Probiotic cell-free supernatant as effective antimicrobials against Klebsiella pneumoniae and reduce antibiotic resistance development.International microbiology : the official journal of the Spanish Society for Microbiology · 2025Article
- Tailoring alginate nanoparticles: influence of reverse micelle templates on structure, size, and encapsulation properties.RSC advances · 2025Article
- Oral dosage forms for drug delivery to the colon: an existing gap between research and commercial applications.Journal of materials science. Materials in medicine · 2025Review
- Systematic review of peptide nanoparticles for improved diabetes outcomes: insights and opportunities.Discover nano · 2025Review
- Niosome Preparation Techniques and Structure-An Illustrated Review.Pharmaceutics · 2025Review
- Linking Short-Chain Fatty Acids to Systemic Homeostasis: Mechanisms, Therapeutic Potential, and Future Directions.Journal of nutrition and metabolism · 2025Review
- Nanotechnology-based Approaches for Targeted Drug Delivery to the Small Intestine: Advancements and Challenges.Current pharmaceutical design · 2025Review
- Fishbone ingestion is a non-negligible cause of intestinal perforation.Frontiers in medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
Abstract
The intestine is essential for the modulation of nutrient absorption and the removal of waste. Gut pathologies, such as cancer, inflammatory bowel diseases (IBD), irritable bowel syndrome (IBS), and celiac disease, which extensively impact gut functions, are thus critical for human health. Targeted drug delivery is essential to tackle these diseases, improve therapy efficacy, and minimize side effects. Recent strategies have taken advantage of both active and passive nanocarriers, which are designed to protect the drug until it reaches the correct delivery site and to modulate drug release via the use of different physical-chemical strategies. In this systematic review, we present a literature overview of the different nanocarriers used for drug delivery in a set of chronic intestinal pathologies, highlighting the rationale behind the controlled release of intestinal therapies. The overall aim is to provide the reader with useful information on the current approaches for gut targeting in novel therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.